• Bisphosphonate medications include alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva). (rheumatology.org)
  • An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? (jabfm.org)
  • In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate. (wikipedia.org)
  • Alendronate belongs to a class of drugs called bisphosphonates. (rxlist.com)
  • Oral and intravenous (IV) bisphosphonates (eg, pamidronate, alendronate, zoledronate) may be beneficial to prevent disease progression, although data are conflicting. (medscape.com)
  • Atypical fractures of the femur have been associated with long-term bisphosphonate therapy. (rheumatology.org)
  • [ 147 ] In addition, a physician reminder in conjunction with a patient risk assessment strategy can result in a reduction in patient fractures and an increase in osteoporosis therapy. (medscape.com)
  • Some patients experience fractures while receiving oral bisphosphonates (BPs) treatment. (bonescore.com)
  • In a cross-sectional study of postmenopausal women on bisphosphonates for at least 4years with good adherence to treatment, 21 patients with incident fractures were compared with 18 treated patients without new fractures. (bonescore.com)
  • Bisphosphonate therapy has emerged as a groundbreaking treatment for osteogenesis imperfecta (OI), a rare genetic disorder that affects the bones and causes them to be brittle and prone to fractures. (monettiapparel.com)
  • These drugs are administered intravenously, bisphosphonates can help strengthen bones and reduce the risk of fractures. (monettiapparel.com)
  • Studies have shown that bisphosphonate therapy can significantly reduce the number of fractures in individuals with OI. (monettiapparel.com)
  • Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models. (ox.ac.uk)
  • Bone loss (osteoporosis) and spinal fractures are serious side effects of this therapy. (cochrane.org)
  • an absolute benefit of 2% fewer people (5% fewer to 1% more) sustaining spinal fractures when taking bisphosphonates. (cochrane.org)
  • Approximately 31 people (range 20 to 145) would need to be treated with bisphosphonates to prevent spinal fractures in one person. (cochrane.org)
  • Based on moderate- to high-certainty evidence, we found that bisphosphonates are beneficial in preventing new spinal fractures and preventing and treating steroid-induced bone loss at the lumbar spine and femoral neck. (cochrane.org)
  • For preventing non-spinal fractures, we found that there was little or no difference whether patients used bisphosphonates or not, although this evidence was low-certainty because the methods used to assess non-spinal fractures were subject to bias. (cochrane.org)
  • Overall, our review supports the use of bisphosphonates to reduce the risk of spinal fractures and in the prevention and treatment of steroid-induced bone loss. (cochrane.org)
  • There was high-certainty evidence that bisphosphonates are beneficial in reducing the risk of vertebral fractures with data extending to 24 months of use. (cochrane.org)
  • Speaking at the American College of Rheumatology's 2018 State of the Art Symposium, Saag said that bisphosphonate "sabbaticals" may cut the risk of osteonecrosis and atypical fractures known to be associated with these agents -- but that substituting alternative drugs may be preferable to stopping all osteoporosis medications. (medpagetoday.com)
  • By now, the risks associated with bisphosphonates when continued for many years are well known to all physicians: femoral fractures and others considered atypical in the senior population, and osteonecrosis of the jaw. (medpagetoday.com)
  • With respect to atypical fractures, Saag said a point to bear in mind is that the risk remains well below that for the osteoporotic fractures that bisphosphonate prevent. (medpagetoday.com)
  • He proposed bisphosphonate "sabbaticals," defined as an extended stoppage of therapy, as opposed to the more traditional "holiday" concept, for patients found to be at risk for adverse bisphosphonate effects and yet still at risk for osteoporotic fractures. (medpagetoday.com)
  • Like bisphosphonates, it inhibits bone resorption (rather than promoting bone formation) and has been tied to osteonecrosis and atypical fractures, though at relatively low rates. (medpagetoday.com)
  • Studies show that drug therapies reduce fractures in postmenopausal women with osteoporosis. (uspreventiveservicestaskforce.org)
  • ABSTRACT Bisphosphonates (BPs) are medications widely used in clinical practice to treat osteoporosis and reduce fragility fractures. (bvsalud.org)
  • A retrospective cohort study [ 1 ] including 39,502 women treated with a bisphosphonate for at least 3 years found a very small overall increase in the risk for osteoporosis-related fractures among women taking a drug holiday vs persistent users of bisphosphonates, but the rate of hip fracture was similar in the two groups. (medscape.com)
  • [ 2 ] Although the data to support a drug holiday are limited, a retrospective comparing patients with atypical femoral fractures and a control group found that the risk for fractures declined by 70% each year after discontinuing bisphosphonate therapy. (medscape.com)
  • Bisphosphonates are associated with a small risk of atypical femoral shaft fractures, which increases with duration of use. (aafp.org)
  • A nested case-control study from Canada matched 716 women 79 to 88 years of age who sustained a subtrochanteric or femoral shaft fracture after receiving bisphosphonate therapy with 3,580 control patients who did not have fractures. (aafp.org)
  • Researchers compared bisphosphonate use and duration of therapy in these groups and in 200 patients older than 50 years who did not have fractures. (aafp.org)
  • However, the odds ratio for a classic fracture was 0.5 (95% CI, 0.3 to 0.9), suggesting a 50% reduction in these types of fractures in women receiving bisphosphonates. (aafp.org)
  • It provides images of the entire femur for assessment of potential atypical femur fractures to monitor the effects of bisphosphonate therapy over time. (acr.org)
  • Also, the incidence of pagetic fractures may be reduced and elevated cardiac output and other vascular disorders may be improved by etidronate disodium therapy. (nih.gov)
  • Poor gastrointestinal absorption, potential gastrointestinal and musculoskeletal adverse effects, irregular dosing regimens, and patient fear of rare but serious complications of therapy such as atypical femoral fracture and osteonecrosis of the jaw-all have a potential negative impact on patient adherence to therapy. (ccjm.org)
  • In spite of lower statistically incidence, the osteonecrosis potentiated by bisphosphonates constitutes alteration of high morbidity, causing drastic decrease of comfort and quality of life for the patients with committed immunity. (bvsalud.org)
  • The objective of this work is to do a review about the pharmacological bisphosphonates action in patients rehabilitated with implants and the aetiology of failures induced by avascular osteonecrosis of the jaws. (bvsalud.org)
  • Bisphosphonates, when administered intravenously for the treatment of cancer, have been associated with osteonecrosis of the jaw (ONJ), with the mandible twice as frequently affected as the maxilla and most cases occurring following high-dose intravenous administration used for some cancer patients. (wikipedia.org)
  • That is, atypical femoral fracture and medication-related osteonecrosis of the jaw are more common in patients with high cumulative doses and longer duration of therapy . (bvsalud.org)
  • In addition to a direct effect on osteoclasts and osteoblasts, some authors suggest that a bisphosphonate induced obliteration of the regional blood vessels could lead to an avascular osteonecrosis of the jaw [17,21,22]. (healthyconnectionsinc.com)
  • Bisphosphonates are associated with a small risk of osteonecrosis of the jaw, which is more common in patients who are older, female, or have poor dental hygiene or cancer. (aafp.org)
  • Physicians should discontinue bisphosphonate therapy in patients who have had a femoral shaft fracture or osteonecrosis of the jaw, and should consider discontinuing bisphosphonate therapy after three to five years in patients with low fracture risk. (aafp.org)
  • A blinded review of adverse events from five randomized controlled trials (11,608 participants) comparing zoledronic acid (Reclast) with placebo or another bisphosphonate found one case of osteonecrosis in the zoledronic acid group and one in the control group. (aafp.org)
  • 6 A 2007 systematic review of eight case reports or case series and three retrospective studies included 26 patients with osteonecrosis of the jaw who were taking bisphosphonates for osteoporosis. (aafp.org)
  • Oral infection is considered to play a critical role in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (BRONJ), and antibiotic therapy has become a mainstay of BRONJ therapy. (nih.gov)
  • Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection, with delayed healing, has been reported in patients taking bisphosphonates. (merck.com)
  • Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a condition found in patients who have received intravenous and oral forms of bisphosphonate therapy for various bone-related conditions. (medscape.com)
  • Bisphosphonate-related osteonecrosis of the jaw (BRONJ) manifests as exposed, nonvital bone involving the maxillofacial structures. (medscape.com)
  • Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is thought to be caused by trauma to dentoalveolar structures that have a limited capacity for bone healing due to the effects of bisphosphonate therapy. (medscape.com)
  • The 2014 update of a position paper from the American Association of Oral and Maxillofacial Surgeons recommended changing the name of bisphosphonate-related osteonecrosis of the jaw (BRONJ) to medication-related osteonecrosis of the jaw (MRONJ), owing to the increased number of maxillary and mandibular osteonecrosis cases that have been linked to other antiresorptive (denosumab) or antiangiogenic treatments. (medscape.com)
  • Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is relatively new to the medical and dental literature. (medscape.com)
  • The true incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) has yet to be determined. (medscape.com)
  • Several recent studies of patients with multiple myeloma and patients with breast cancer who received intravenous aminobisphosphonate therapy for metastatic bone lesions demonstrated 6-11% of the patients developed bisphosphonate-related osteonecrosis of the jaw (BRONJ). (medscape.com)
  • The incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) has been strongly correlated with the aminobisphosphonates pamidronate (Aredia) and zoledronic acid (Zometa) and is even higher in patients who have had recent dental extractions. (medscape.com)
  • Kahn et al evaluated the association of osteonecrosis of the jaw with bisphosphonate use. (medscape.com)
  • Data that links the incidence of osteonecrosis of the jaw and its etiologic factors are limited, and the incidence of osteonecrosis of the jaw in the general population (ie, those not taking bisphosphonates) is unknown. (medscape.com)
  • Evidence is insufficient to confirm a causal link between low-dose bisphosphonate use in osteoporosis with osteonecrosis of the jaw. (medscape.com)
  • Osteonecrosis of the jaw is primarily associated with high-dose bisphosphonate use in cancer patients. (medscape.com)
  • Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a condition in which bones of the maxillofacial skeleton, in particular the tooth-bearing areas, become necrotic and exposed to the oral cavity. (medscape.com)
  • Bisphosphonate-related osteonecrosis of the jaw (BRONJ) can be spontaneous, commonly appearing in the mylohyoid ridge area. (medscape.com)
  • Bisphosphonate-related osteonecrosis of the jaw (BRONJ) may also be caused by trauma, such as a tooth extraction or dental surgery. (medscape.com)
  • [ 7 , 8 ] Injury to the bone in these patients via tooth extraction, dental surgery, or mechanical trauma is thought to initiate bisphosphonate-related osteonecrosis of the jaw (BRONJ). (medscape.com)
  • Participants who completed the PRISM study were invited to take part in a 3-year extension in which the same treatment strategies were continued but where zoledronic acid was used as the bisphosphonate of first choice in the intensive arm," they write. (medscape.com)
  • Preclinical trials sought to target MMP-9 and angiogenesis with a prototypical MMP inhibitor and with a bisphosphonate, zoledronic acid (ZA), revealing both to be antiangiogenic, producing effects comparable to a Mmp9 gene KO in impairing angiogenic switching, progression of premalignant lesions, and tumor growth. (jci.org)
  • However, intravenously administered bisphosphonates do appear to provide a continuous effect on bone for the duration of their use. (medscape.com)
  • Oral bisphosphonates pose a higher risk of heartburn and esophagitis than their intravenously administered counterparts. (medscape.com)
  • Especially after treatment by nitrogen made up of bisphosphonates intravenously an incidence of 5%-19% has been reported [18-20]. (healthyconnectionsinc.com)
  • Bisphosphonate Therapy - Includes the following medications: pamidronate and zoledronate. (mdinteractive.com)
  • Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. (smw.ch)
  • The FDA says that any patient on bisphosphonates who presents with thigh or groin pain must be evaluated to rule out femoral fracture. (acr.org)
  • There have been suggestions to start an aromatase inhibitor patient on bisphosphonates. (medscape.com)
  • Most women taking bisphosphonates fall into the low-to-moderate fracture risk category, and a drug holiday should be considered. (medscape.com)
  • As opposed to old em in vivo /em research that feature higher bone relative density to decreased bone tissue turnover, newer research show the potential of bisphosphonates to improve osteoblast proliferation and differentiation in bone tissue marrow-derived mesenchymal stem cells (MSC) and osteoblasts [13-15]. (healthyconnectionsinc.com)
  • In September 2011, denosumab (Prolia) was approved by the U.S. Food and Drug Administration (FDA) to increase bone mass in women at high risk for fracture who are receiving adjuvant aromatase inhibitor therapy for breast cancer. (medscape.com)
  • Clinical guidelines recommend treatment with denosumab and intravenous bisphosphonates (IVBPs) to prevent SREs. (ibm.com)
  • All patients had ≥6 months of data before the first BM diagnosis date (index date) and were followed for ≥6 months from the index date until the earliest of inpatient death, initiation of denosumab/IVBP therapy or end of data. (ibm.com)
  • In patients with such a history or who fail to at least maintain bone mineral density while on a bisphosphonate, consideration should be given to switching to a drug such as denosumab. (medscape.com)
  • Other more recent drug therapies include teriparatide and denosumab. (smw.ch)
  • In this issue of the Cleveland Clinic Journal of Medicine , Ashcherkin and colleagues 1 review how bone turnover markers (BTMs) can be used to monitor oral bisphosphonate treatment efficacy and patient adherence. (ccjm.org)
  • Intravenous bisphosphonates can give fever and flu-like symptoms after the first infusion, which is thought to occur because of their potential to activate human γδ T cells. (wikipedia.org)
  • 4 Nonsystematic reviews suggest that it occurs in up to 20% of patients with cancer who receive intravenous bisphosphonates, but in only about 0.04% of patients with osteoporosis who receive oral bisphosphonates. (aafp.org)
  • Conclusions The above data suggest a limited influence of bisphosphonates on osteoblast proliferation, except for zoledronate. (healthyconnectionsinc.com)
  • The nitrogen-containing bisphosphonates zoledronate and ibandronate were compared to the non-nitrogen-containing bisphosphonate clodronate. (healthyconnectionsinc.com)
  • Therapy should be individualized based on each patient's clinical scenario, with the risks and benefits of treatment discussed between the clinician and patient. (medscape.com)
  • Saag noted that, at the outset of bisphosphonate therapy, steps can be taken to reduce some of the risks. (medpagetoday.com)
  • Risks of long-term use of BPs The extended use of antiresorptive therapy has drawn attention to two extremely rare, although severe, adverse events. (bvsalud.org)
  • Clinician and patient in this case should discuss the potential benefits and risks of continued bisphosphonate therapy, and shared decision-making about this option should be documented. (medscape.com)
  • What are the risks of bisphosphonate use? (aafp.org)
  • The substantial and continuing increase in prescribing prevalence of bisphosphonates reinforces the need for research into the long-term risks and benefits of these therapies. (ox.ac.uk)
  • This finding is reassuring for the first 5 years after a woman starts aromatase-inhibitor therapy, but we don't know what the long-term risks to bone health are after 5 years. (medscape.com)
  • We found that the BMD of the femoral neck was 2.06% higher in the bisphosphonate group (1.45% to 2.68% more) than in people with no treatment. (cochrane.org)
  • Approximately five people (range 4 to 7) would need to be treated with bisphosphonates for 12 months for one person to see a minimally important difference in BMD at the femoral neck. (cochrane.org)
  • Bisphosphonates, which inhibit resorption of bone by osteoclasts, have been studied extensively in breast cancer. (medscape.com)
  • Bisphosphonates are a class of drugs that inhibit the breakdown of bone tissue. (monettiapparel.com)
  • Bisphosphonates inhibit the digestion of bone by encouraging osteoclasts to undergo apoptosis, or cell death, thereby slowing bone loss. (wikipedia.org)
  • Harms of drug therapies for osteoporosis depend on the specific medication used. (uspreventiveservicestaskforce.org)
  • However, many conventional and investigational drug therapies combine drugs that attack cancer cells at different points in their growth cycles. (lls.org)
  • Bisphosphonates work by reducing the turnover of bone which lowers the risk of fracture. (rheumatology.org)
  • However, the clinical applications of bone turnover markers (BTMs) can extend beyond these roles: BTMs can be utilized to determine when to start or end a bisphosphonate "holiday," and they can also measure treatment response. (ccjm.org)
  • The value of these byproducts of osteoclastic activity lies in the observation that bone turnover decreases in response to treatment with antiresorptive agents such as bisphosphonates. (ccjm.org)
  • Long-term suppression of bone turnover with intensive bisphosphonate therapy in patients with Paget's disease of bone does not appear to provide any clinical benefit over less intensive symptomatic therapy, suggest findings from the extension study of the Paget's Disease: Randomized Trial of Intensive versus Symptomatic Management (PRISM-EZ). (medscape.com)
  • Increasing evidence indicates that in postmenopausal women with breast cancer, adjuvant bisphosphonate treatment not only improves bone density but also decreases bone metastasis and improves overall survival. (medscape.com)
  • Emerging data suggest that adjuvant therapy with bisphosphonates may prevent disease recurrence and prolong survival, specifically in postmenopausal women. (medscape.com)
  • The Early Breast Cancer Trialists' Collaborative Group found that in postmenopausal women with early breast cancer, adjuvant bisphosphonate therapy produced highly significant reductions in recurrence (rate ratio [RR] 0.86, P =0.002), distant recurrence (RR 0.82, P =0.0003), bone recurrence (RR 0.72, P =0.0002), and breast cancer mortality (RR 0.82, P =0.002). (medscape.com)
  • In postmenopausal women, the selective estrogen receptor modulator raloxifene is occasionally administered instead of bisphosphonates. (wikipedia.org)
  • Consider risk-reduction therapy with tamoxifen 20 mg PO qDay (in pre- and postmenopausal women) or raloxifene 60 mg PO qDay (in postmenopausal women) for 5 years in patients with estrogen receptor (ER)-positive DCIS. (medscape.com)
  • Postmenopausal women at high risk for recurrence can be evaluated for adjuvant treatment with a bisphosphonate. (medscape.com)
  • The ATAC trial recruited postmenopausal women with invasive primary breast cancer and randomized them to receive adjuvant treatment with Arimidex, tamoxifen, or combination therapy. (medscape.com)
  • Osteoporosis patients who received bisphosphonates showed a higher incidence of AF occurrence than those that were not treated with bisphosphonates (P = .015). (tmu.edu.tw)
  • thus, the incidence was significantly lower than that in the patients treated with bisphosphonates (P = .007). (tmu.edu.tw)
  • In addition, the patients who were treated with vitamin D had a lower incidence of AF than did those who were not treated with either vitamin D or bisphosphonates (P = .074). (tmu.edu.tw)
  • Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. (ox.ac.uk)
  • OBJECTIVE: The purpose of this study was to examine recent trends in the prescribing of hormone therapy for menopause, tibolone, and bisphosphonate preparations for the prevention or treatment of osteoporosis, in the UK in relation to publication of research evidence on the health effects of hormone therapy and subsequent changes in prescribing advice. (ox.ac.uk)
  • METHODS: Individual patient-level data were obtained on the prescribing of hormone therapy, tibolone, and bisphosphonates by general practitioners in the UK between 1991 and 2005 to women aged 40 years and older in the UK General Practice Research Database. (ox.ac.uk)
  • Prescribing prevalence was also calculated for subcategories of hormone therapy and bisphosphonates. (ox.ac.uk)
  • RESULTS: Prescribing of hormone therapy to women aged 40 years and older increased between 1991 and 1996 and remained fairly stable between 1997 and 2001. (ox.ac.uk)
  • Hormone therapy prescribing has fallen by about 50% since 2002. (ox.ac.uk)
  • Tibolone, a selective tissue estrogenic activity regulator, is prescribed much less commonly than hormone therapy but shows a similar pattern. (ox.ac.uk)
  • CONCLUSIONS: Trends in the prescribing of hormone therapy in the UK appear to closely reflect new epidemiological evidence and prescribing advice. (ox.ac.uk)
  • It is likely that the substantial fall in hormone therapy and tibolone prescribing seen since 2002 is a direct consequence of the publication of Women's Health Initiative trial results and subsequent changes in advice given by the Committee on Safety of Medicines. (ox.ac.uk)
  • Treatments include hormone therapy, radiotherapy, bisphosphonates and chemotherapy. (cancerresearchuk.org)
  • After five years of medications by mouth or three years of intravenous medication among those at low risk, bisphosphonate treatment can be stopped. (wikipedia.org)
  • In 2009 bisphosphonates were "among the only class of medications that has survived placebo-controlled studies showing statistically significant improvement (in CRPS) with therapy. (wikipedia.org)
  • But the oral bisphosphonates remain the most widely prescribed antifracture drugs and continue to pose clinical challenges such as measuring therapeutic efficacy and ensuring patient adherence. (ccjm.org)
  • CHICAGO -- While the widely reported adverse effects of long-term bisphosphonate treatment in osteoporosis patients are certainly real, undertreatment of fracture risk now appears to be gaining, a prominent rheumatologist warned in a lecture here. (medpagetoday.com)
  • Background Bisphosphonates are widely used in the clinical treatment of bone diseases with increased bone resorption. (healthyconnectionsinc.com)
  • However, therapy may be delayed by physicians due to perceived low risk of SREs or for other clinical reasons. (ibm.com)
  • Given its track record in clinical use with limited toxicity, ZA holds promise as an "unconventional" MMP-9 inhibitor for antiangiogenic therapy of cervical cancer and potentially for additional cancers and other diseases where MMP-9 expression by infiltrating macrophages is evident. (jci.org)
  • The non-nitrogen-containing Mitoxantrone supplier bisphosphonate clodronate, however, did not significantly influence cyclin D1 and collagen gene expression. (healthyconnectionsinc.com)
  • Our experience using the latest therapies, and our ongoing myeloma research ensures you receive the best possible care. (dukehealth.org)
  • Bisphosphonates are used to treat high levels of calcium in the blood caused by certain cancers, including myeloma. (lls.org)
  • Background Bisphosphonates are trusted in the scientific treatment of bone tissue diseases with an increase of bone tissue resorption [1] such as for example Paget's disease, osteoporosis, and malignant diseases like multiple metastasis or myeloma towards the bone tissue. (healthyconnectionsinc.com)
  • Bisphosphonates won't slow or stop the spread of cancer, but they can slow bone breakdown, increase bone thickness and reduce bone pain and fracture risk. (lls.org)
  • Fracture risk should be reassessed after 3-5 years of therapy, and those women who continue to be at high risk for fracture should continue on treatment. (medscape.com)
  • Women who take a drug holiday should have their fracture risk reassessed in 2-4 years, and those who experience a substantial increase in risk should be restarted on therapy. (medscape.com)
  • Treat with one of the following (followed by antiresorptive therapy, e.g. (fpnotebook.com)
  • Bone metastases: Bisphosphonate therapy. (epnet.com)
  • Bisphosphonates are a group of medicines used to treat osteopenia or osteoporosis, which are conditions associated with thin or fragile bones that are at increased risk for fracture. (rheumatology.org)
  • Bisphosphonates make bones stronger which can help ease bone pain. (epnet.com)
  • Bisphosphonates can delay the development of skeletal-related events in women with metastatic breast cancer and show promise in preventing bone loss induced by chemotherapy or hormonal therapy. (medscape.com)
  • Evidence suggests that the use of bisphosphonates would be useful in the treatment of complex regional pain syndrome, a neuro-immune problem with high MPQ scores, low treatment efficacy and symptoms which can include regional osteoporosis. (wikipedia.org)
  • This study using limited sample size indicated that oral antibiotic therapy may have a limited efficacy on the bacterial population associated with BRONJ lesions. (nih.gov)
  • He cited 2011 data indicating that, for bisphosphonate therapy, the number needed to harm for atypical fracture was 417 over 3 years, whereas the number needed to treat for osteoporotic hip and vertebral fracture was 91 and 14, respectively. (medpagetoday.com)
  • The authors evaluated prescription data and found that of 52,595 women receiving bisphosphonates for more than five years, only 71 (0.13%) sustained an atypical fracture. (aafp.org)
  • After adjusting for sex and for corticosteroid and vitamin D use, the use of bisphosphonates was associated with an odds ratio of 49.7 for an atypical fracture compared with the no-fracture group (95% CI, 15.9 to 155.1). (aafp.org)
  • The authors calculated that the relative risk for atypical fracture in women receiving bisphosphonates was 47.5 (95% CI, 25.6 to 87.3). (aafp.org)
  • In the setting of metastatic disease, bisphosphonates have little or no effect on survival. (medscape.com)
  • However, these findings opened the opportunity for the use of BPs as adjuvant therapy for this population of women with bone metastatic disease. (aacrjournals.org)
  • The aim of treatment in the symptomatic arm was to treat bone pain likely due to PDB, initially with analgesics or, if pain control was inadequate, with bisphosphonates. (medscape.com)
  • In the symptomatic PRISM-EZ arm, patients received a bisphosphonate only if bone pain likely due to increased PDB metabolic activity was present. (medscape.com)
  • A total of 270 patients in the intensive-therapy arm transitioned into PRISM-EZ as did 232 patients originally assigned to the symptomatic arm. (medscape.com)
  • Nevertheless, the risk of adverse effects rises with duration of therapy whereas the preventive benefit does not. (medpagetoday.com)
  • Our objective was to determine the benefits and harms of bisphosphonates for adults on long-term steroid therapy. (cochrane.org)
  • With its potential to significantly improve bone strength and reduce pain, this therapy has revolutionized the management of OI. (monettiapparel.com)
  • Moreover, women on a drug holiday experienced significantly better fracture outcomes compared with women who continued to receive bisphosphonate prescriptions but were less than 50% adherent to the dosing schedule. (medscape.com)
  • Patients with invasive breast cancer that is ER+ or progesterone receptor positive (PR+) should be considered for adjuvant endocrine therapy with tamoxifen or aromatase inhibitors (AIs). (medscape.com)
  • This is less of an issue with bisphosphonates, which accumulate in bone and are actually re-released into the circulation at pharmacologically active levels (perhaps contributing to their adverse effects). (medpagetoday.com)
  • He credited the ACP guideline with highlighting the need for awareness of bisphosphonates' adverse effects and the concept of interrupting treatment. (medpagetoday.com)
  • Nonpharmacologic preventive measures include modification of general lifestyle factors, such as increasing weight-bearing and muscle-strengthening exercise, which epidemiologic studies have linked to lower fracture rates, and ensuring optimum calcium and vitamin D intake as adjunct to active antifracture therapy. (medscape.com)
  • People were randomly assigned to receive either bisphosphonate treatment (alone or with calcium or vitamin D, or both) or 'no treatment' (given calcium or vitamin D or a placebo). (cochrane.org)
  • They should also take calcium and vitamin D supplements during anastrozole therapy," he said. (medscape.com)
  • The USPSTF found that the risk of serious adverse events, upper gastrointestinal events, or cardiovascular events associated with the most common class of osteoporosis medication (bisphosphonates) is no greater than small. (uspreventiveservicestaskforce.org)
  • According to previously reported trial results, Arimidex was superior to tamoxifen or combination therapy for preventing recurrence of breast cancer. (medscape.com)
  • Cite this: Deprescribing Bisphosphonates: The Crowdsourced Opinion - Medscape - Jul 24, 2019. (medscape.com)
  • Addressing the Controversy: Do Bisphosphonates Directly Affect Primary Tumors? (aacrjournals.org)
  • A 2017 Cochrane review found that for people with early breast cancer, bisphosphonate treatment may reduce the risk of the cancer spreading to the person's bone, however, for people who had advanced breast cancer bisphosphonate treatment did not appear to reduce the risk of the cancer spreading to the bone. (wikipedia.org)
  • Further research is needed to explore the long-term effects and optimal dosage of bisphosphonates in the management of OI. (monettiapparel.com)
  • Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3-5 years after an initial 3-5 years of treatment. (wikipedia.org)